Advertisement

Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist

Published:January 24, 2023DOI:https://doi.org/10.1016/j.ejca.2022.12.030
      Suspected progression of metastatic melanoma should always be confirmed by biopsy and pathological examination. Indeed, many non-cancerous lesions can mimic metastases and lead to inappropriate management of patients in the absence of histology. This can be particularly true in the context of certain therapeutic backgrounds associated with bone vulnerability such as chronic treatment with the antiretroviral drug tenofovir as illustrated in this patient's case where a suspicion of bone metastasis was rectified after bone biopsy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. PrEP-guidelines-2017.pdf [Internet]. [cited 2022 Sep 6]. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.

        • Grant P.M.
        • Cotter A.G.
        Tenofovir and bone health.
        Curr Opin HIV AIDS [Internet]. 2016 May; 11 ([cited 2022 Sep 6];Available from:): 326-332
        • Wang S.
        • Kortenaar J.L.
        • Hull M.W.
        • Arbess G.
        • Owen J.R.
        • Tan D.H.
        Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey.
        PPA [Internet]. 2018 Oct; 12 ([cited 2022 Sep 6]; Available from:): 2197-2204
        • Baranek B.
        • Wang S.
        • Cheung A.M.
        • Mishra S.
        • Tan D.H.
        The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
        Antivir Ther [Internet]. 2020 Jan; 25 ([cited 2022 Sep 6]; Available from:): 21-32
        • Warming L.
        • Hassager C.
        • Christiansen C.
        Changes in bone mineral density with age in men and women: a longitudinal study.
        Osteoporos Int [Internet]. 2002 Feb 1; 13 ([cited 2022 Sep 7]; Available from:): 105-112https://doi.org/10.1007/s001980200001
        • Cohen S.
        • Levy R.M.
        • Keller M.
        • Boling E.
        • Emkey R.D.
        • Greenwald M.
        • et al.
        Risedronate therapy prevents corticosteroid-induced bone loss : a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
        Arthritis & Rheum [Internet]. 1999; 42 ([cited 2022 Sep 7]; Available from:): 2309-2318
      2. Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Reviews. :10.